Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Prolymphocytic, T-Cell 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

glofitamab 2Rituximab 2Cyclophosphamide 2zanubrutinib 1pirtobrutinib 1pegfilgrastim 1obinutuzumab 1mirabegron 1Vincristine 1Specimen Handling 1Prednisolone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Lenalidomide 1Doxorubicin 1Dexrazoxane 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Dendritic Cell Sarcoma, Interdigitating × Lisaftoclax × Clear all
NCT07255963 2025-12-01

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
29 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡